🇺🇸 FDA
Patent

US 11642339

Methods of treating symptoms of gastroparesis using velusetrag

granted A61KA61K31/4704A61K31/55

Quick answer

US patent 11642339 (Methods of treating symptoms of gastroparesis using velusetrag) held by Theravance Biopharma R&D IP, LLC expires Mon May 04 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Theravance Biopharma R&D IP, LLC
Grant date
Tue May 09 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 04 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K31/4704, A61K31/55, A61K9/4858, A61K9/4866